
Commentary|Videos|December 8, 2024
Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax
Author(s)Marcella Ali Kaddoura, MD
Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.
Advertisement
Marcella Ali Kaddoura, MD, assistant professor, Department of Medicine, the Division of Myeloma, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, discusses an investigation into the genomic determinants of clinical outcomes in patients with t(11;14)-positive multiple myeloma harboring IHG/CCND1 rearrangements who have been treated with venetoclax (Venclexta). These findings were shared by Kaddoura and colleagues at the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































